Regulatory Roundup: FDA Takes Action Against Drug Manufacturer and Distributor - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Takes Action Against Drug Manufacturer and Distributor

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has issued a consent decree of condemnation, forfeiture, and permanent injunction against H&P Industries, The Triad Group, and three individuals to prevent them from manufacturing and distributing products from their Wisconsin facility and other locations. “The Triad Group distributes and H&P Industries manufactures a variety of over-the-counter drug products including povidone-iodine and benzalkonium chloride antiseptic products, cough and cold products, nasal sprays, suppositories, medicated wipes, antifungal creams, and hemorrhoidal wipes,” according to the agency announcement. H&P had failed to comply with cGMPs as demonstrated in inspections conducted by FDA between 2009 and 2011, and has initiated five product recalls because of bacterial contamination since December 2010. Operations cannot be resumed until the companies prove to have an acceptable Quality Assurance and Quality Control program.

The agency also approved redesigned drug container label produced by Merck that address a new standardized format aimed at improving readability and understanding of product and strength differentiation, according to an FDA release. The company’s labeling project included revising 34 container labels for 16 solid oral drugs.

The International Conference on Harmonization steering committee and expert working groups held one of their twice-annual meetings last week in Cincinnati, Ohio. Summaries of the meeting are expected soon.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here